Put companies on watchlist
Biotest AG
ISIN: DE0005227235
WKN: 522723
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Biotest AG · ISIN: DE0005227235 · EQS - Company News (133 News)
Country: Germany · Primary market: Germany · EQS NID: 1718261
04 September 2023 12:10PM

Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years


EQS-News: Biotest AG / Key word(s): Personnel
Biotest AG: Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years

04.09.2023 / 12:10 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

 

PRESS RELEASE

 

Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years

 

  • Dr Jörg Schüttrumpf to remain Chief Scientific Officer (CSO) of Biotest AG for another 5 years
  • Appointment as Chief Scientific Innovation Officer of Grifols S.A.


Dreieich, 4 September 2023. The Supervisory Board of Biotest AG extended the Management Board contract of Dr Jörg Schüttrumpf (49) by 5 years until 31 August 2028. This is in recognition of his many years of successful work as Head of Research and Development and, since the beginning of 2022, as Chief Scientific Officer (CSO) on the Management Board of Biotest AG.

 

As 'Chief Scientific Officer', Dr Schüttrumpf is responsible for research and development within the Biotest Group, including drug safety and regulatory affairs. Dr Schüttrumpf has been Head of Global Research at Biotest AG since 2012 and Head of Research and Development since 2015.

 

In addition, the Spanish parent company of Biotest AG, Grifols S.A., has asked Dr Schüttrumpf to assume the role of 'Chief Scientific Innovation Officer' for the entire Grifols Group. In this role, he will drive the strategic growth focus as a provider of innovative therapeutics for both companies.

 

"We are very pleased to have Dr Schüttrumpf as a long-term member of the Board of Management and congratulate him on his additional new role in the Grifols Group. He has been very successful in developing the research and development area at Biotest and is a leader with an impressive track record," emphasises Dr Bernhard Ehmer, Chairman of the Supervisory Board of Biotest AG.

 

 

 

 

About Biotest:

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

 

 


IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com


 

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN: DE0005227201
Preference shares: securities’ ID No.  522723; ISIN: DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hannover, München, Stuttgart, Tradegate

 

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

 

 

 

 



04.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: ir@biotest.com
Internet: www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1718261

 
End of News EQS News Service

1718261  04.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1718261&application_name=news&site_id=boersengefluester
Visual performance / price development - Biotest AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.